The FDA granted approval for Orion’s Clevor, an eye drop indicated for the induction of vomiting in dogs, in June 2020. Under the terms of the related agreement, Vetoquinol will have the right to sell and market Clevor (ropinirole) in the USA.
On Aug. 1, 2020, Vetoquinol acquired the rights for the Drontal and Profender products in the EU and the UK. Effective Jan. 1, 2021, Orion will have the right to sell and market Vetoquinol’s Drontal and Profender products in Finland, Hungary and Romania. Drontal product range is used for the treatment and control of internal parasites in cats and dogs and Profender for the treatment and control of internal parasites in cats.
These new distribution agreements expand the current collaboration between the two companies under which Vetoquinol has been distributing Orion Animal Health’s sedative products in several European countries since February 2015.
“I’m very pleased to expand our fruitful collaboration with Vetoquinol and have a trusted partner to distribute the latest approved Orion Animal Health innovation in the USA. Also, it is important for us that we can continue to sell Drontal and Profender in our home market Finland and expand the distribution to Hungary and Romania”, says Niclas Lindstedt, Vice President of Orion Animal Health.
“We are delighted to reinforce our partnership with Orion. Our Drontal and Profender product ranges will benefit from an efficient distribution network in Finland, Hungary and Romania. Moreover, Vetoquinol is proud to be the veterinary laboratory chosen by Orion to develop this innovative drug, Clevor (ropinirole), in the USA. This is a new milestone in our cooperation that demonstrates Vetoquinol’s strong selling capabilities and expertise in this key market” says Matthieu Frechin, CEO of Vetoquinol.
This content was originally published here.